Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | ASPH | Q12797 | 2/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4249059 | 0.98 | KDM4E (0.39) | KDM4EKMT2ACCR5L3MBTL1PDE10A | |
| SCHEMBL9504653 | 0.98 | KDM4E (0.39) | KDM4EKMT2ACCR5L3MBTL1PDE10A | |
| Hydrogen Peroxide SCHEMBL28248198 | 0.83 | NTRK1 (0.48) | KDM4EKMT2ACCR5TDP1ALDH1A1 | |
| SCHEMBL6628045 | 0.83 | CSNK1A1 (0.38) | KDM4EKMT2ACCR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL31662998 | 0.83 | CSNK1A1 (0.38) | KDM4EKMT2ACCR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL10766873 | 0.81 | CYP3A4 (0.39) | KDM4EKMT2ACCR5L3MBTL1TDP1 | |
| SCHEMBL411769 | 0.81 | ITGB1 (0.36) | CCR5TDP1ALDH1A1ITGB1ITGA4 | |
| SCHEMBL7612137 | 0.81 | L3MBTL1 (0.38) | KDM4EKMT2ACCR5L3MBTL1PDE10A | |
| SCHEMBL9684174 | 0.81 | KDM4E (0.50) | KDM4EKMT2ACCR5L3MBTL1TDP1 | |
| SCHEMBL5780556 | 0.81 | KDM4E (0.50) | KDM4EKMT2AL3MBTL1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | claimed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | claimed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | claimed |
| WO-2023233033-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2023-12-07 | — | — | WO | claimed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | claimed |
| WO-2022117882-A2 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2022-06-09 | — | — | WO | claimed |
| CN-107827871-A | A kind of preparation method of Determination of Omeprazole Metabolites in Human | 梯尔希（南京）药物研发有限公司 | 2018-03-23 | — | — | CN | claimed |
| US-20050187248-A1 | Synthesis of piperidine and piperazine compounds as CCR5 antagonists | LEONG WILLIAM (US) | 2005-08-25 | — | — | US | claimed |
| EP-1490352-A1 | SYNTHESIS OF PIPERIDINE AND PIPERAZINE COMPOUNDS AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040024217-A1 | Synthesis of piperidine and piperazine compounds as CCR5 antagonists | SCHERING CORPORATION | 2004-02-05 | — | — | US | claimed |
| WO-2003084950-A1 | SYNTHESIS OF PIPERIDINE AND PIPERAZINE COMPOUNDS AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2003-10-16 | — | — | WO | claimed |
| EP-0744395-B1 | PROCESS FOR PRODUCING DIMETHYLAMINE | MITSUBISHI RAYON CO (JP) | 2001-10-31 | — | — | EP | claimed |
| EP-0272903-B1 | PROCESS FOR PRODUCING A POLYARYLENE SULFIDE | Tosoh Corporation (JP) | 1993-07-21 | — | — | EP | claimed |
| EP-0325061-A2 | Process for producing poly (para-phenylene-sulfide) | Tosoh Corporation (JP) | 1989-07-26 | — | — | EP | claimed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| US-3975389-A | BRONCHODILATOR | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | KDM4E 4042/4885KMT2A 2245/4885CCR5 1106/4885 |
| US-20050187248-A1 | Synthesis of piperidine and piperazine compounds as CCR5 antagonists | CCR5, CCR2, CXCR5 | KDM4E 1354/4885KMT2A 2544/4885CCR5 1/4885 |
| US-20040024217-A1 | Synthesis of piperidine and piperazine compounds as CCR5 antagonists | CCR5, CCR2, CXCR5 | KDM4E 1503/4885KMT2A 2619/4885CCR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.